GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Tangible Book per Share

Venus Medtech (Hangzhou) (HKSE:02500) Tangible Book per Share : HK$3.34 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Venus Medtech (Hangzhou)'s tangible book value per share for the quarter that ended in Dec. 2023 was HK$3.34.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Venus Medtech (Hangzhou) Tangible Book per Share Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Tangible Book per Share Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial 6.51 8.63 10.33 4.45 3.34

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.33 5.34 4.45 3.56 3.34

Competitive Comparison of Venus Medtech (Hangzhou)'s Tangible Book per Share

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Price-to-Tangible-Book falls into.



Venus Medtech (Hangzhou) Tangible Book per Share Calculation

Venus Medtech (Hangzhou)'s Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3194.543-0-1723.256)/441.011
=3.34

Venus Medtech (Hangzhou)'s Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3194.543-0-1723.256)/441.011
=3.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Venus Medtech (Hangzhou)  (HKSE:02500) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Venus Medtech (Hangzhou) Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Traded in Other Exchanges
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines